Core Viewpoint - Tianyu Digital Technology announced an expected net profit loss attributable to shareholders of the listed company for 2025, ranging from 41 million to 59 million yuan, showing a significant reduction in losses compared to the previous year's loss of 118 million yuan, with a year-on-year decrease of 49.98% to 65.24% [1] Financial Performance - The expected net profit loss after deducting non-recurring items is projected to be between 116 million and 134 million yuan, compared to a loss of 195 million yuan in the same period last year, indicating a year-on-year reduction in losses of 31.32% to 40.54% [1] - The primary reason for the losses is attributed to the planned impairment provisions for certain equity and controlling subsidiaries' related assets, along with the impact of non-recurring gains and losses amounting to approximately 75 million yuan [1] - Excluding asset impairments, the company's main business operations are expected to achieve profitability [1]

Core Viewpoint - The company 康为世纪 (688426.SH) expects to reduce its net loss for the year 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -1.12 billion to -914.41 million, reflecting a year-on-year reduction in loss of 28.91% to 41.83% [1] Financial Performance - The projected net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to range from -1.43 billion to -1.23 billion, indicating a year-on-year reduction in loss of 20.64% to 31.90% [1] - The main reason for the performance change is attributed to the recovery phase of the life sciences and diagnostic reagent industry, along with the ongoing market expansion of new businesses that have not yet achieved economies of scale [1] Revenue Growth - The reduction in net loss is primarily due to an increase in main business revenue, with significant overall sales revenue growth during the reporting period [1] - The growth is mainly driven by the rapid expansion of the company's technology service businesses, including gene sequencing and gene synthesis [1]